公开(公告)号：US20240309103A1

公开(公告)日：2024-09-19

申请号：US18680910

申请日：2024-05-31

Applicant: REGENERON PHARMACEUTICALS, INC.

Inventor： Michael E. DUNN ,  Jia SU ,  Jason MASTAITIS ,  Jesper GROMADA ,  Lori C. MORTON

IPC: C07K16/28 ,  A61K9/00 ,  A61K39/395 ,  A61K45/06 ,  A61P3/04 ,  A61P9/02 ,  A61P9/12

CPC classification number: C07K16/2869 ,  A61K9/0019 ,  A61K39/3955 ,  A61K45/06 ,  A61P3/04 ,  A61P9/02 ,  A61P9/12 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present invention provides monoclonal antibodies that bind to the natriuretic peptide receptor 1 (NPR1) protein, and methods of use thereof. In various embodiments of the invention, the antibodies are fully human antibodies that bind to NPR1. In some embodiments, the antibodies of the invention are useful for activating NPR1 activity, thus providing a means of treating or preventing a disease, disorder or condition associated with NPR1 in humans.

公开(公告)号：US20190002555A1

公开(公告)日：2019-01-03

申请号：US15746565

申请日：2016-07-21

Applicant: REGENERON PHARMACEUTICALS, INC.

Inventor： Michael E. DUNN ,  Lori C. MORTON ,  Yonaton RAY ,  Jee H. KIM

IPC: C07K16/26 ,  A61K39/395 ,  A61K45/06

Abstract: The present invention provides monoclonal antigen-binding proteins that bind to the cardiac glycoside marinobufagenin (MBG), and methods of use. In various embodiments of the invention, the antigen-binding proteins are fully human antigen-binding proteins that bind to MBG. In some embodiments, the antigen-binding proteins of the invention are useful for inhibiting or neutralizing MBG activity, thus providing a means of treating or preventing a MBG-associated disease or disorder selected from the group consisting of hypertension, myocardial fibrosis, uremic cardiomyopathy, heart failure, myocardial infarction, renal failure, renal fibrosis and pre-eclampsia.

公开(公告)号：US20240059780A1

公开(公告)日：2024-02-22

申请号：US18485241

申请日：2023-10-11

Applicant: REGENERON PHARMACEUTICALS, INC.

Inventor： Michael E. DUNN ,  Jia SU ,  Jason MASTAITIS ,  Jesper GROMADA ,  Lori C. MORTON

IPC: C07K16/28

CPC classification number: C07K16/2869 ,  A61P9/02

Abstract: The present invention provides monoclonal antibodies that bind to the natriuretic peptide receptor 1 (NPR1) protein, and methods of use thereof. In various embodiments of the invention, the antibodies are fully human antibodies that bind to NPR1. In some embodiments, the antibodies of the invention are useful for activating NPR1 activity, thus providing a means of treating or preventing a disease, disorder or condition associated with NPR1 in humans.